We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Early Diagnosis of Tularemia Accomplished by Flow Cytometry

By LabMedica International staff writers
Posted on 02 Oct 2019
Tularemia is a zoonotic disease that occurs in the Northern Hemisphere and is caused by Francisella tularensis. More...
In Europe, more than 500 cases are reported annually and Turkey and the USA also have substantial disease burdens.

No clinical or laboratory manifestations are pathognomonic for tularemia; preliminary diagnosis is based on exposure risk and compatible clinical presentation. Clinical manifestations include the ulceroglandular, glandular, oroglandular, and oculoglandular forms; septicemic (typhoidal) form; and respiratory form.

Scientists from the České Budějovice Hospital (České Budějovice, Czech Republic) and their colleagues used laboratory records and local hospital and unit diagnostic indices, and retrospectively identified all cases of tularemia that were managed in the infectious disease units at two hospital during January 1, 2003, through December 31, 2015. The control group included a consecutive group of ill adults who were investigated for possible tularemia in the same two units during January 1, 2012, through December 31, 2015.

For serologic testing, the team used a commercial agglutination test, the Tularemia Diagnostic Set. They also performed blood cultures using BacT/ALERT 3D and species was determined by polymerase chain reaction (PCR). The investigators used a flow cytometry–based test for quantifying the percentage of CD3+ T cells with the CD4–/CD8– phenotype for predicting tularemia. The samples were processed using either a Cytomics FC500 (before 2014) or Navios (starting in 2013) flow cytometer and CXP (for Cytomics FC500).

The team reported that the median percentage of CD3+/CD4–/CD8– T cells in peripheral blood was higher in tularemia patients (19%, 95% CI 17%–22%) than in controls (3%, 95% CI 2%–3%). When they used 8% as the cutoff, this test’s sensitivity was 0.953 and specificity 0.895 for distinguishing cases from controls. The CD3+/CD4–/CD8– T cells increased a median of seven days before tularemia serologic test results became positive.

The authors concluded that flow cytometry analyses of peripheral blood samples showing a percentage of CD3+/CD4–/CD8– T cells greater than 8% supports a presumptive clinical diagnosis of tularemia and initiation of specific antimicrobial therapy days to weeks before the diagnosis can be confirmed serologically. This more rapid test is a useful addition to the diagnostic work-up for tularemia that can help public health teams managing waterborne outbreaks and inhalation infection clusters speed up diagnosis and treatment and thus contain pathogen spread. The study was published in the October 2019 issue of the journal Emerging Infectious Diseases.

Related Links:
České Budějovice Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.